{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
monomethyl fumarate
to a specific field?
Status:
US Approved Rx
(2002)
Source:
BLA103964
(2002)
Source URL:
First approved in 2002
Source:
BLA103964
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2001)
Source:
BLA103949
(2001)
Source URL:
First approved in 2001
Source:
BLA103949
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(1994)
Source:
BLA103411
(1994)
Source URL:
First approved in 1994
Source:
BLA103411
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:ciletatug vedotin [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:misitatug blivedotin [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:becotatug vedotin [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:felmetatug vedotin [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:lonigutamab ugodotin [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:mecbotamab vedotin [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03500380: Phase 2/Phase 3 Interventional Active, not recruiting Breast Neoplasms
(2018)
Source URL:
Class:
PROTEIN
